L-Nutra receives $47 million to advance longevity nutrition technology

Moderna CEO Makes New Investment in Longevity Science Nutrition Program Development Company

Nutrient technology company L-Nutra has successfully completed its first round of Series D fundraising, securing a total of $47 million. The company specializes in scientific longevity nutrition programs designed to promote healthy living and longevity.

Founded in 2009 by the University of Southern California and Dr. Walter Longo, director of the Longevity Institute at USC, L-Nutra has deep expertise in the science of intermittent fasting (fasting for more than two days), which has been shown to induce It becomes a disease. A specific stress that leads to cellular rejuvenation. The company’s ongoing research and development efforts are focused on the concept that intermittent fasting may be used to treat diseases in patients by triggering this survival defense mode.

L-Nutra is the developer of Fasting Mimic Technology, a special nutritional formulation platform that provides nutrition to the body while maintaining cells in a fasted state, providing many health benefits and biological aging benefits from fasting. You have a period increase.

The investment round was led by Brentwood Associates and Stephane Bancel, CEO of biotech giant Moderna, best known for its pioneering work in mRNA vaccine development.

Bansel said, “I have been thoroughly impressed with the science led by Dr. Walter Longo and the products that L-Nutra has brought to market based on his research. I believe their first food technology product, the 5 Day Fasting Imitation Diet, is an important tool to ensure people live long and healthy lives. I made this personal investment to help L-Nutra continue its development and ensure that more people have access to its science-based products.

L-Nutra has completed more than 30 clinical trials and obtained 200 patents worldwide. The company has partnered with 18 academic research centers, allowing it to develop two pipelines aimed at improving human longevity and addressing age-related diseases: L-Nutras ProLon brand on promoting healthy aging through rejuvenation It focuses on improving cellular and metabolic health. Meanwhile, L-Nutra Health is designed to increase patients’ chances of recovery from conditions such as diabetes, cancer, autoimmune diseases and cardiovascular disease through nutrition as medicine.

Dr. Joseph Anton, CEO of L-Nutra, said, “We are proud to have the support of Mr. Stephen Bunsel, one of the most successful biotech leaders of our time, who recently extended human lifespan with Moderna’s Covid vaccine. “His personal investment in our company reinforces confidence in our cutting-edge science and continued support of our global mission to increase lifespan and longevity worldwide. With Mr. Bancel’s financial support, we can continue to expand ProLon into global markets.” “We’re also able to increase access to our first diabetes recovery program, enabling patients to significantly reduce their reliance on medication in many cases.”